DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 3.6%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s share price fell 3.6% during trading on Tuesday . The company traded as low as $2.41 and last traded at $2.42. 5,238 shares were traded during mid-day trading, a decline of 87% from the average session volume of 41,772 shares. The stock had previously closed at $2.51.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DMAC. Oppenheimer restated an “outperform” rating and issued a $6.00 price target (down from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum began coverage on DiaMedica Therapeutics in a report on Wednesday. They issued a “buy” rating and a $8.00 price target on the stock.

DiaMedica Therapeutics Price Performance

The business has a 50-day moving average of $2.80 and a 200-day moving average of $2.69. The firm has a market cap of $96.03 million, a price-to-earnings ratio of -4.08 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). As a group, equities analysts anticipate that DiaMedica Therapeutics Inc. will post -0.69 EPS for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Paragon Associates & Paragon Associates II Joint Venture increased its position in shares of DiaMedica Therapeutics by 6.4% in the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after acquiring an additional 30,000 shares during the last quarter. Avantax Advisory Services Inc. acquired a new position in DiaMedica Therapeutics during the fourth quarter worth approximately $36,000. Finally, Stonebridge Capital Advisors LLC acquired a new position in DiaMedica Therapeutics during the third quarter worth approximately $52,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.